Top 1% Biotech Yo-Yos, But Hits All-Time High, on NASH Enthusiasm – Investor’s Business Daily

  1. Top 1% Biotech Yo-Yos, But Hit Record, On NASH EnthusiasmInvestor Business Daily
  2. Viking Therapeutics’ NASH drug passes mid-term trial, shares jumpReuters
  3. Viking Therapeutics Announces Positive Top Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)Yahoo finance
  4. Chasing Madrigal, Viking sails higher after NASH therapy kills mid-stage testFierceBiotech
  5. Bulls Blast Viking Therapeutics Stock on Trial DataSchaeffer Research
  6. See full coverage on Google News

Leave a Comment

Your email address will not be published. Required fields are marked *